Medicxi put 40m into two Sosei spin off companies
Sosei Group Corporation has spun out two programmes of its neurology pipeline into two newly created companies funded by venture fund Medicxi.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1551 entries already.
Entries by Thomas Gabrielczyk
EMA greenlights two orphan drugs and two biosimilars
/in News/by Thomas GabrielczykEMAs human medicines committee (CHMP) recommended six medicines for approval at its January 2019 meeting.
Hitachi expands European reach in cell and gene therapy
/in News/by Thomas GabrielczykHitachi Chemical Co. Ltd. is set to takeover cell and gene therapy CDMO apceth Biopharma GmbH to get a foothold in Europe, the second largest market for advanced therapies after the […]
Dewpoint Therapeutics kicks off with $60m financing
/in News/by Thomas GabrielczykDewpoint Therapeutics has attracted interested of investors with a completely new approach that might cure a huge array of devasting diseases.
IPO: Marinomed sets offer price
/in News/by Thomas GabrielczykMarinomed has set the offer price for its IPO at Vienna Stock Exchange at the lower limit of 75 per new share.
Novozymes partners with Carbios subsidiary Carbiolice
/in News/by Thomas GabrielczykNovozymes has entered into a partnership with French Carbios and its subsidiary Carbiolice, which aim to launch degradable bioplastics with limited lifespan for the packaging industry by 2020.
Biomarker predicts response to TNF blockers
/in News/by Thomas GabrielczykA new assay that accurately measures how arthritis patients respond to treatment with TNFalpha blockers such as adalimumab, open up the way to predict efficacy.
UK launches new payment model for antimicrobials
/in News/by Thomas GabrielczykIn order to incentivise drug companies to re-enter development of antibiotics, the UK government announced it will establish a licence model to assure developers sufficient return on investments (ROI).
BioNtech swallows MAB Discovery antibody unit
/in News/by Thomas GabrielczykImmunoncology and vaccine specialist BioNTech AG is broadening its antibody discovery capabilities by acquiring MAB Discoverys antibody generation unit.
Clariant inks cellulosic biodiesel pact with ExxonMobil/REG
/in News/by Thomas GabrielczykSwiss fine chemicals specialist Clariant has hammered out a R&D pact with ExxonMobil and Renewable Energy Group (REG) Inc to combine technologies in order of producing biodiesel from cellulose